Anti-PD1 抗体 [NAT105] (ab52587)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Mouse monoclonal [NAT105] to PD1
- Suitable for: WB, Flow Cyt, IHC-Fr, ICC/IF, IHC-P
- Reacts with: Human
Related conjugates and formulations
リコンビナント抗体で、ロット間での高い再現性を実現
- 異なるロット間での安定した再現性
- 容易なスケールアップ
- 評価試験による特異性の確認済み
- 倫理基準に準拠 - アニマル・フリーの生産
製品の概要
-
製品名
Anti-PD1 antibody [NAT105]
PD1 一次抗体 製品一覧 -
製品の詳細
Mouse monoclonal [NAT105] to PD1 -
由来種
Mouse -
アプリケーション
適用あり: WB, Flow Cyt, IHC-Fr, ICC/IF, IHC-Pmore details -
種交差性
交差種: Human -
免疫原
Tissue, cells or virus. This information is proprietary to Abcam and/or its suppliers.
-
特記事項
Please note that PD-1 is expressed variably in different tissues and that optimisation may be required depending on the tissue used for the experiment.
Western blot protocol advice:
Due to low expression of PD-1, we recommend loading a high amount of sample (100 µg) to detect the band for PD-1. Human tonsil and YT cell line lysates are suitable positive controls.
This product has switched from a hybridoma to recombinant production method on 1st November 2024.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
バッファー
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 0.05% BSA, 40% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
精製度
Protein A purified -
ポリ/モノ
モノクローナル -
クローン名
NAT105 -
アイソタイプ
IgG1 -
軽鎖の種類
kappa -
研究分野
関連製品
-
Alternative Versions
- Anti-PD1 antibody [NAT105] - BSA and Azide free (ab201811)
- Anti-PD1 antibody [NAT105] - Rabbit IgG (Chimeric) (ab216352)
- Alexa Fluor® 488 Anti-PD1 antibody [NAT105] (ab220300)
- Alexa Fluor® 647 Anti-PD1 antibody [NAT105] (ab220301)
- PE Anti-PD1 antibody [NAT105] (ab220302)
- Anti-PD1 antibody [NAT105] (ab234444)
- Alexa Fluor® 555 Anti-PD1 antibody [NAT105] (ab280864)
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
-
Related Products
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab52587の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
WB |
1/1000. Predicted molecular weight: 32 kDa.
|
|
Flow Cyt |
1/1000.
|
|
IHC-Fr | (1) |
1/10000.
|
ICC/IF |
1/100.
|
|
IHC-P | (7) |
1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
|
特記事項 |
---|
WB
1/1000. Predicted molecular weight: 32 kDa. |
Flow Cyt
1/1000. |
IHC-Fr
1/10000. |
ICC/IF
1/100. |
IHC-P
1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. |
ターゲット情報
-
機能
Possible cell death inducer, in association with other factors. -
関連疾患
Genetic variation in PDCD1 is associated with susceptibility to systemic lupus erythematosus type 2 (SLEB2) [MIM:605218]. Systemic lupus erythematosus is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue. It affects principally the skin, joints, kidneys and serosal membranes. It is thought to represent a failure of the regulatory mechanisms of the autoimmune system. -
配列類似性
Contains 1 Ig-like V-type (immunoglobulin-like) domain. -
発生段階
Induced at programmed cell death. -
細胞内局在
Membrane. - Information by UniProt
-
参照データベース
- Entrez Gene: 5133 Human
- Omim: 600244 Human
- SwissProt: Q15116 Human
- Unigene: 158297 Human
-
別名
- CD279 antibody
- CD279 antigen antibody
- hPD 1 antibody
see all
プロトコール
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (282)
ab52587 は 282 報の論文で使用されています。
- Pedersen K et al. Galectin-3 interacts with PD-1 and counteracts the PD-1 pathway-driven regulation of T cell and osteoclast activity in Rheumatoid Arthritis. Scand J Immunol 97:e13245 (2023). PubMed: 36537046
- Hakroush S & Tampe B Association between Loss of Immune Checkpoint Programmed Cell Death Protein 1 and Active ANCA-Associated Renal Vasculitis. Int J Mol Sci 24:N/A (2023). PubMed: 36769297
- Xu X et al. Clinical implications and molecular features of tertiary lymphoid structures in stage I lung adenocarcinoma. Cancer Med 12:9547-9558 (2023). PubMed: 36880167
- Zhou T et al. Artificial intelligence-based comprehensive analysis of immune-stemness-tumor budding profile to predict survival of patients with pancreatic adenocarcinoma. Cancer Biol Med 20:196-217 (2023). PubMed: 36971107
- Hayashi Y et al. Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors. Br J Cancer 128:2175-2185 (2023). PubMed: 37016103